CVS Health Corporation (NYSE:CVS) stock consolidated at the key level of around $110, signaling that it was time to exit. The healthcare solutions company has returned a negative 7% year-to-date. It should be noted that the loss in the year comes at the back of a strong rally throughout 2021. The stock rose from a low of around $72 in January 2021 to top $110 at the start of this year.
Evidently, CVS Health’s weakness can be attributed to profit-taking after the stock hit the key resistance of above $110. The weakness is bound to continue as the stock faces imminent pressure after breaking below the consolidation zone.
Are you looking for fast-news, hot-tips and market analysis?
Sign-up for the Invezz newsletter, today.
On Wall Street, CVS has a hold rating at Deutsche Bank with a price target of $110, which the stock has already hit. The rating is a downgrade from the previous buy recommendation by the bank. Some other analysts, including Raymond James, have a higher target of $120. However, we remain less optimistic the stock will rise to $120 in the short-term as weaknesses persist. Consequently, investors could be looking to cut positions.
CVS retreats after hitting resistance
Technically, CVS is coming down from an overbought level of $110 when the RSI was 78. The current weakness is bound to continue, with an established support zone around $70-$80. The stock could also settle at around $90 and begin a bullish reversal from there. The quarter results on May 04 could trigger the rise from $90 if results beat estimates. We still maintain the stock could fall to $70-$80, the established support.
Summary
Investors should sell CVS Health stock ahead of earnings and buy lower. The stock could fall up to $70-80, the key support zone. If earnings beat estimates, the stock could reverse around $90.
Where to buy right now
To invest simply and easily, users need a low-fee broker with a track record of reliability. The following brokers are highly rated, recognised worldwide, and safe to use:
- Etoro, trusted by over 13m users worldwide. Register here >
- bitFlyer, simple, easy to use and regulated. Register here >
*Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.
Source: https://invezz.com/news/2022/04/30/sell-cvs-health-for-a-chance-to-buy-at-these-potential-levels/